BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July
